Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | FAAH | O00519 | 5/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6894122 | 1.00 | CA2 (0.47) | CA2FAAHABCB1ZDHHC7CTSK | |
| SCHEMBL12437946 | 1.00 | CA2 (0.47) | CA2FAAHABCB1ZDHHC7CTSK | |
| SCHEMBL12930095 | 1.00 | CA2 (0.47) | CA2FAAHABCB1ZDHHC7CTSK | |
| SCHEMBL10087918 | 0.85 | CA2 (0.47) | CA2FAAHABCB1ZDHHC7LMNA | |
| SCHEMBL6894231 | 0.85 | CA2 (0.47) | CA2FAAHABCB1ZDHHC7LMNA | |
| SCHEMBL14873546 | 0.85 | CA2 (0.47) | CA2FAAHABCB1ZDHHC7LMNA | |
| SCHEMBL12961319 | 0.85 | CA2 (0.47) | CA2FAAHABCB1ZDHHC7LMNA | |
| SCHEMBL6894229 | 0.85 | CA2 (0.47) | CA2FAAHABCB1ZDHHC7LMNA | |
| SCHEMBL18597022 | 0.85 | LMNA (0.55) | CA2FAAHABCB1ZDHHC7LMNA | |
| SCHEMBL8041217 | 0.85 | LMNA (0.55) | CA2FAAHABCB1ZDHHC7LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580417-B2 | Prodrugs of heteraromatic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-02-28 | — | — | US | disclosed |
| US-9580417-B2 | Prodrugs of heteraromatic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-02-28 | — | — | US | disclosed |
| US-20160009713-A1 | Prodrugs of Heteraromatic Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-01-14 | — | — | US | disclosed |
| US-9107911-B2 | Prodrugs of heteraromatic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-08-18 | — | — | US | disclosed |
| US-20120015866-A1 | Prodrugs of Heteraromatic Compounds | ALKERMES, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166194-A1 | Asenapine Prodrugs | GRIN1, SCN1B, GRIN2B | CA2 4238/4885FAAH 193/4885ABCB1 557/4885 |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | SLC1A2, BDNF, MAOB | CA2 3182/4885FAAH 210/4885ABCB1 758/4885 |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | HTR5A, HTR2C, HTR2B | CA2 3676/4885FAAH 164/4885ABCB1 231/4885 |
| US-20120015866-A1 | Prodrugs of Heteraromatic Compounds | CYP2D6, CYP2B6, CYP3A4 | CA2 2668/4885FAAH 735/4885ABCB1 6/4885 |
| US-20160009713-A1 | Prodrugs of Heteraromatic Compounds | CYP2D6, CYP2B6, CYP3A4 | CA2 2668/4885FAAH 735/4885ABCB1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.